LAS VEGAS, Oct. 10, 2017 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), today announced that its industry-dominating brand of hemp-derived cannabidiol (CBD) oil finished products, PlusCBD Oil™, will be exhibiting at the Academy of Integrative Health & Medicine (AIHM) Annual 2017 Conference, held on October 22-25, 2017 at Paradise Point Resort & Spa in San Diego, California. This will be the Company’s third time exhibiting at this forward-thinking healthcare Conference and Expo.
Known as “The Integrative Health & Medicine Conference of the Year,” AIHM Conference brings together over 1,100 doctors, health clinicians, researchers and students to learn from visionaries in the field of integrative health, earn continuing education credits and network with likeminded professionals. This community-centric conference features lectures, panels, small group discussions, workshops, evening events and experiential programs. Over the last three years, CV Sciences’ consumer products division has focused on distributing their PlusCBD Oil™ brand to healthcare providers nationwide.
"AIHM’s Annual Conference brings together thought leaders in the field of integrative health and nutritional medicine, and showcases companies like CV Sciences who share in that vision," comments Stuart Tomc, VP of Human Nutrition at CV Sciences. "The demand for phytocannabinoids such as CBD is here, and practitioners continue to seek out reliable information on current practical and nutritional benefits of hemp-derived CBD. We are excited to continue to showcase our growing array of products showing the tremendous potential hemp-derived CBD may hold for overall health and look forward to educating attendees at this year’s Conference."
VISIT BOOTH 15: CV Sciences invites attendees to visit Booth 15 to learn more about their botanical-based CBD product line. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT: Robert Haag, Managing Director IRTH Communications [email protected] 866-976-4784


Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 



